The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Nivolumab With or Without Ipilimumab in Gastroesophageal Junction Cancer

Yelena Y. Janjigian, MD
Published Online:6:13 PM, Thu June 22, 2017

Yelena Y. Janjigian, MD, attending physician, Memorial Sloan Kettering Cancer Center, discusses findings of CheckMate-032, a study of nivolumab (Opdivo) with or without ipilimumab (Yervoy) in patients with advanced/metastatic chemotherapy-refractory gastric, esophageal, or gastroesophageal junction cancer.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.